Search results
Is Eli Lilly Stock A Buy After FDA Advisors Back Its Alzheimer's Drug?
Investor's Business Daily· 3 days agoZepbound is projected to generate $4.5 billion in sales. In 2029, analysts expect the two drugs to...
5 Must-Buy S&P 500 Stocks at 52-Week High With Room to Run
Zacks· 3 days agoU.S. stock markets have maintained their northbound journey in the first half of 2024 after an impressive 2023. The three major stock indexes — the Dow, ...
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
Motley Fool via Yahoo Finance· 5 days agoBy comparison, the average forward multiple among big pharma stocks is around 17 and the S&P 500...
‘Inside Out 2’ Is a Blockbuster. Are Movie Chains Finally Back?
Barrons.com· 6 days agoFEATURE Walt Disney Inside Out 2 blowout opening just might give investors in movie theater stocks...
Taylor Swift kicks off UK Eras shows as some fans wonder if singer is ready to say 'So long, London'
The News-Times· 1 day agoTaylor Swift fans enjoy parsing the singer-songwriter’s lyrics for references to her romantic life...
How to buy IPO stock
Bankrate via AOL· 5 days agoGetting in on an initial public offering — more commonly called an IPO — seems like the ticket to riches. Buy a hot new stock and get in on the ground...
Blockbuster India IPO Plan Drives Hyundai Shares to Record High
Bloomberg via Yahoo Finance· 7 days ago(Bloomberg) -- Plans for what may be one of India’s largest-ever initial public offerings boosted...
Want an Extra $100 in Annual Dividend Income? Invest $1,320 in These 3 High-Yield Stocks | The...
The Motley Fool· 12 hours agoWould you like to widen the stream of passive income you can expect each year? Investors who are attracted to truly passive income generation may want to consider AT&T (T 1.60%), PenantPark ...
Where Will Amgen Be in 5 Years?
The Motley Fool via AOL· 3 days agoBy then, interest rates will likely be lower, and concerns about its debt levels might not be as high as they are today. Should you buy Amgen's stock? Amgen is trading at ...
Eli Lilly's Growth Prospects Just Got a Huge Upgrade
Motley Fool via Yahoo Finance· 3 days agoThe results were similar to those achieved from Biogen's Leqembi, which obtained approval last year. At its peak, donanemab could easily be a blockbuster...
